Navigation Links
Oncologists Rank Aloxi's Marketing Message Most Influential in the Chemotherapy-Induced Nausea and Vomiting Drug Market
Date:12/4/2008

WALTHAM, Mass., Dec. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Eisai/Helsinn Healthcare's Aloxi's marketing message ("Better in acute, better in delayed") is rated the most influential by oncologists in the chemotherapy-induced nausea and vomiting drug market. Oncologists accurately identified Aloxi's messages with the brand, highlighting the strength of the Aloxi messaging campaign.

According to the new report entitled Brands & Strategies: Chemotherapy-Induced Nausea and Vomiting, U.S. physicians rate Aloxi higher than Merck's Emend in terms of top-of-mind therapy despite Aloxi and Emend launching in the same year in the United States. Emend scored low in terms of brand recognition with less than 20 percent of oncologists identifying the correct messages associated with the brand. Surveyed oncologists rate Emend's marketing messages ("More complete prevention comes from two directions" and "Used in more than 2.7 million chemotherapy cycles over 5 years") in the bottom three most influential messages, with the latter being the least identifiable message. Despite this, both Emend and Aloxi are forecasted to dominate the chemotherapy-induced nausea and vomiting market in 2012.

"Promotional spending on chemotherapy-induced nausea and vomiting drug therapies in the United States is relatively low compared to other therapeutic areas," said Marcus Hoyle, analyst at Decision Resources. "In 2007 $61 million was spent by the leading competitors (Merck, MGI Pharma/Eisai, Roche and Sanofi-Aventis) in the United States to promote their respective brands."

About Brands & Strategies

The Brands & Strategies report series from Decision Resources reveals what it takes to be successful in a pharmaceutical market. It offers the most comprehensive commercial analysis of the brands and strategies of competing companies so they can better position themselves in a market and plan future strategy based on what competitors are doing. Brands & Strategies is the first and only report series to bring together all the competitive information elements pharma companies need to make informed decisions about their brands and next-steps.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Heather Hilty              Elizabeth Marshall
    Decision Resources         Decision Resources, Inc.
    781-296-2536               781-296-2563
    hhilty@dresources.com      emarshall@dresources.com

'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. MedTrust Online Collaborates With Oracle and Dell to Provide Oncologists With the Next Generation Tool for Personalized Care Delivery
2. Society of Gynecologic Oncologists 39th Annual Meeting on Womens Cancer to Include Sessions on HPV and Cervical Cancer
3. South Florida Gynecologic Oncologists Begin Using LUMA(R) Cervical Pre-Cancer Imaging Device
4. Despite Oncologists Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
5. Society of Gynecologic Oncologists to Host 39th Annual Meeting on Womens Cancer
6. 91 Percent of Oncologists Polled Report Adverse Patient Events as Result of CMS National Coverage Decision on ESAs
7. Expert Neurosurgeons and Neuro-oncologists to Speak at 6th Annual Brain Tumor Awareness Day Convention
8. Jefferson oncologists show focused radiation is effective as surgery against nerve tumor
9. Leading Oncologists from Across the Country Hold Emergency Meeting on New Government Reimbursement Policy for Medicare Patients with Cancer
10. Society of Gynecologic Oncologists Provides Guidelines for Offering Genetic Risk Assessment to Women With a Personal or Family History of Breast, Ovarian, Uterine or Colorectal Cancer
11. Jefferson radiation oncologists use real-time system to plant seeds against cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... of the GlycoMark test throughout the Northeast U.S. , GlycoMark is the ... diabetes. The GlycoMark test provides a clinically proven one- to two-week measure of ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, a leading ... Nova Skin Sciences division, recently announced the launch of Allumière Antiaging Cream, a ... of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract and Vitamin ...
(Date:4/27/2017)... and DENVER (PRWEB) , ... April 27, 2017 ... ... Health, the nation’s leading respiratory hospital, based in Denver, Colorado, announced an agreement ... is enabled by the continuing support of the Jane and Leonard Korman Family ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Cogentix Medical, ... focused on providing the Urology, Uro/Gyn and Gynecology ... that Ash Keswani has joined the Company as ... this newly created position, Mr. Keswani will report ... CEO. "Our organization is delighted that ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ABBV), ... percent (n=145/146) of chronic hepatitis C virus (HCV) ... or 6 and compensated cirrhosis (Child-Pugh A) achieved ... 12 ) with its investigational, pan-genotypic regimen of ... were seen following 12 weeks of G/P treatment ...
Breaking Medicine Technology: